Literature DB >> 11412231

The interaction of nitric oxide and prostaglandins in the control of corporal smooth muscle tone: evidence for production of a cyclooxygenase-derived endothelium-contracting factor.

S Minhas1, J J Cartledge, I Eardley, A D Joyce, J F Morrison.   

Abstract

OBJECTIVE: To investigate the interaction of endothelium-derived nitric oxide (NO) and prostaglandins (PGs) in regulating corporal smooth muscle tone in vitro. Materials and methods Strips of rabbit corpus cavernosum were mounted in organ chambers for the measurement of isometric tension. Strips were submaximally contracted with noradrenaline and concentration-response curves (CRCs) to acetylcholine (ACh) were constructed before and after treatment with 5 micromol/L atropine, 20 micromol of the cyclooxygenase inhibitor indomethacin and 10 micromol of the PGH2/thromboxane A2 receptor antagonist SQ29548. The NO synthase (NOS) inhibitors L-NG-monomethyl arginine (L-NMMA) and L-NG-nitroarginine (L-NOARG) were added to strips at tonic tension in the presence and absence of indomethacin, and after this CRCs to ACh were constructed.
RESULTS: The addition of ACh to strips produced a concentration-dependent relaxation which was inhibited by atropine. Indomethacin, but not SQ29548, significantly increased relaxation to ACh. Relaxation to ACh was impaired by L-NMMA, but adding ACh to strips treated with L-NOARG resulted in contractile responses, whilst both effects were reversed by indomethacin. L-NMMA and L-NOARG led to increases in tonic tone which were unaffected by indomethacin.
CONCLUSIONS: In rabbit corpus cavernosum there is a tonic release of NO which does not appear to be inhibited by a vasoconstrictor prostanoid. Endothelium-dependent relaxation to ACh results in the dual production of NO and a cyclooxygenase-derived endothelium contracting factor which acts in opposition to NO; this factor is unlikely to act on PGH2/TXA2 receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11412231     DOI: 10.1046/j.1464-410x.2001.02178.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  4 in total

1.  Antiplatelet (aspirin) therapy as a new option in the treatment of vasculogenic erectile dysfunction: a prospective randomized double-blind placebo-controlled study.

Authors:  Zeki Bayraktar; Selami Albayrak
Journal:  Int Urol Nephrol       Date:  2018-01-17       Impact factor: 2.370

2.  Long-Term Aspirin Administration Has No Effect on Erectile Function: Evidence from Adult Rats and Ageing Rat Model.

Authors:  Tao Li; Changjing Wu; Fudong Fu; Wenfeng Xiong; Feng Qin; Jiuhong Yuan
Journal:  Sci Rep       Date:  2019-05-28       Impact factor: 4.379

3.  Hydrochlorothiazide Potentiates Contractile Activity of Mouse Cavernosal Smooth Muscle.

Authors:  Thiago Gagliano-Jucá; Mauro Napolitano; Fernanda Del Grossi Ferraz Carvalho; Rafael Campos; Fabíola Zakia Mónica; Mário Angelo Claudino; Edson Antunes; Anibal Gil Lopes; Gilberto De Nucci
Journal:  Sex Med       Date:  2016-03-19       Impact factor: 2.491

4.  Potential Effect of the Circadian Clock on Erectile Dysfunction.

Authors:  Tao Li; Yunjin Bai; Yiting Jiang; Kehua Jiang; Ye Tian; Zhen Wang; Yong Ban; Xiangyi Liang; Guangheng Luo; Fa Sun
Journal:  Aging Dis       Date:  2022-02-01       Impact factor: 6.745

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.